RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
https://doi.org/10.20996/1819-6446-2012-8-3-453-456
Abstract
The possibilities of antithrombotic therapy in atrial fibrillation are highlighted. The alternative antithrombotic agents, including rivaroxaban presented along with the traditional drugs (acetyl-salicylic acid, warfarin). Efficacy and safety of rivaroxaban is considered on the basis of the results of the ROCKET-AF study.
About the Author
M. Yu. Gilyarov
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Hart R. G., Pearce, L. A., Rothbart, R. M. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. JACC 2000; 35: 183–187.
2. Hart R. G., Pearce, L. A., Koudstaal, P. J. Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial. Stroke 2004; 35: 948–951.
3. Hohnloser S. H., Pajitnev, D., Pogue, J. et al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Sub-study. JACC 2007; 50: 2156–2161.
4. Hart R. G., Pearce, L. A., Aguilar, M. I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146: 857–867.
5. Olesen J. B., Lip G. Y. H., Lindharsen J. et al. Risk of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a “real world” nationalwide cohort study. Thromb. Haemostasis 2011; 106: 739–749.
6. The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 2009; 360: 2066–2078.
7. Gilyarov M.Yu., Generozov E.V., Magomadova M.U. et al. Factors affecting the dose of warfarin in patients sfibrillyatsiey fibrillation. Kardiologiya i Serdechno-sosudistaya Khirurgiya 2008; (1): 65–68. Russian (Гиляров М.Ю., Генерозов Э.В., Магомадова М.У. и др. Факторы, влияющие на дозировку варфарина у пациентов с фибрилляцией предсердий. Кардиология и Сердечно-сосудистая Хирургия 2008; (1): 65–68).
8. Gilyarov M.Yu., Generozov E.V., Magomadova M.U. et al. Subunit 1 of vitamin K epoxode reductase gene polymorphism: prevalence and impact on warfarin dose among residents of the Moscow region. Kardiologiya i Serdechno-sosudistaya Khirurgiya 2009; (3): 36–39. Russian (Гиляров М.Ю., Генерозов Э.В., Магомадова М.У. и др. Полиморфизм гена субъединицы 1 витамин К эпоксидредуктазы: распространенность и влияние на дозировку варфарина у жителей Московского региона. Кардиология и Сердечно-сосудистая Хирургия 2009; (3): 36–39).
9. Cleland J. G. F., Cowburn, P. J., Falk, R. H. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J 1996; 17: 674–681.
10. Hylek E. M., Skates, S. J., Sheehan, M. A. et al. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation. N Engl J Med 1996; 335: 540–546.
11. Lip G. Y. H., Niewulaat R., Pisters R. et al. Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 187: 263–272.
12. ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883–891.
Review
For citations:
Gilyarov M.Yu. RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2012;8(3):453-456. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-3-453-456
Views:
703
Email this article 